Subscribe
shutterstock_1532109092_sundry_photography
Sundry Photography / Shutterstock.com
16 June 2022Big PharmaSarah Speight

Glycosyn sues Abbott over infant formula method

Biotech company Glycosyn has sued Abbott Laboratories for allegedly infringing its patented method for manufacturing a key ingredient in infant formula milk, found in three of Abbott’s infant formula products under the Similac brand.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Abbott sues former employee for alleged trade secrets theft
1 June 2023   Ex-scientist faces lawsuit for allegedly downloading thousands of files before leaving for a rival | Abbott seeks damages for ‘flagrant misconduct’ brought to its attention by successive employer.
Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Americas
Abbott unit prevails in dispute over catheter patent
25 March 2021   In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Abbott sues former employee for alleged trade secrets theft
1 June 2023   Ex-scientist faces lawsuit for allegedly downloading thousands of files before leaving for a rival | Abbott seeks damages for ‘flagrant misconduct’ brought to its attention by successive employer.
Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Americas
Abbott unit prevails in dispute over catheter patent
25 March 2021   In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.

More on this story

Big Pharma
Abbott sues former employee for alleged trade secrets theft
1 June 2023   Ex-scientist faces lawsuit for allegedly downloading thousands of files before leaving for a rival | Abbott seeks damages for ‘flagrant misconduct’ brought to its attention by successive employer.
Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Americas
Abbott unit prevails in dispute over catheter patent
25 March 2021   In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims